Transcend Therapeutics is a clinical-stage biotechnology company focused on developing rapid-acting treatments for neuropsychiatric diseases. The company aims to address mental health conditions such as Post-Traumatic Stress Disorder (PTSD) and Major Depressive Disorder (MDD), particularly for patients who do not respond to existing therapies. The company’s lead program, TSND-201 (methylone), is being developed as a next-generation neuroplastogen designed to deliver fast and durable therapeutic effects. Its research emphasizes innovative psychoactive compounds that can improve outcomes while minimizing common limitations of traditional psychiatric medications. Backed by venture funding and an experienced leadership team with multiple FDA approvals, Transcend Therapeutics continues to advance clinical trials and expand its pipeline of mental health treatments.
On-site & Remote